佐科威总统周二（8月11日）前往万隆巴查查兰大学医学系(FK Unpad)参观PT Bio Farma制药厂与中国科兴（SinoVac）合作进行第三期临床试验的新冠疫苗。根据计划将有1,620名志愿者参加这项新冠疫苗第三阶段临床试验，预计将于2021年1月完成，若试验取得成功效果，将获得印尼食品与药物管理局（BPOM）许可授权在当地接种大量生产和投日使用。
总统还参观了PT Bio Farma制药厂的新冠疫苗生产设施。总统说，Bio Farma作为疫苗生产工厂的能力已获得世界认可。其产品已遍及全球140多个国家。包括小儿麻痹症疫苗，肺病结核（TB）疫苗等药品。
陪同总统参观活动的有卫生部长德拉旺.阿古斯.布特兰多(TerawanAgusPutranto)，国营企业部(BUMN)部长，兼处理新冠疫情和国家经济复苏委员会执行主席埃里克.多希尔(Erick Thohir)，印尼国家抗灾机构(BNPB)主任兼新冠病毒疫情防控工作小组组长多尼中将（Doni Monardo），内阁秘书帕拉摩诺•阿侬（PramonoAnung）和西爪哇省长利德宛•卡米尔(RidwanKamil)。
埃里克.多希尔8月4日参观巴查查兰大学医学系PT Bio Farma制药厂生产准备状况时表示，政府需要大量的资金采购和疫苗注射。根据他的估计，购买疫苗，生产并其注射到1亿6000万至1亿9000万我国民众中将花费约45亿美元或大约65.9兆盾。
(Bandung comprehensive news) Last week, as World Health Organization (WHO) warned that there may never be a special cure for the Covid-19 virus, people are looking forward to the breakthrough of the Covid-19 vaccine development as soon as possible, and are hoping there are some vaccines that effectively curb the continued spread of Covid-19 virus. Before developing effective cures and vaccines for Covid-19 virus, basic public health protocols and disease control measures must be implemented to prevent the further spread of the epidemic.
On Tuesday (August 11), President Jokowi went to the Faculty of Medicine of Padjajaran University (FK Unpad) in Bandung to visit the PT Bio Farma pharmaceutical factory in cooperation with SinoVac for the third phase of clinical trials of the Covid-19 vaccine. According to the plan, 1,620 volunteers will participate in the third phase clinical trial of the Covid-19 vaccine, which is expected to be completed in January 2021. If the trial is successful, it will be licensed and registered by the Indonesian Food and Drug Administration (BPOM) for mass production and daily usage.
The President witnessed the first batch of 19 volunteers who participated in the third phase of clinical trials of the Covid-19 vaccine.
Kusnandi Rusmil, Operation Head of the third phase clinical trial research team of the Covid-19 vaccine at Padjajaran University, said on Monday (10th Aug) that volunteers who participating in the third phase of the Covid-19 vaccine clinical trial must first take a swab test. In fact, 20 volunteers were checked, but based on the swab test results, only 19 people passed the swab test to participate in this clinical trial. Kusnandi Rusmil continued to say that 1,200 volunteers have signed up to participate in the third phase of the Covid-19 vaccine clinical trials so far.
The President also visited the Covid-19 vaccine production factory of PT Bio Farma Pharmaceutical facility. Jokowi President said, Bio Farma’s capacity as a vaccine production factory has been recognized worldwide. Its products have been distributed in more than 140 countries worldwide, including polio vaccine, tuberculosis (TBC) vaccine and other drugs.
The companions to the President’s visit were Minister of Health, Dr. Terawan Agus Putranto; Minister of State Enterprises (BUMN) and Executive Chairman of the COVID-19 and National Economic Recovery Committee, Erick Thohir; Director of the Indonesian National Disaster Relief Agency (BNPB) and leader of the COVID-19 Prevention and Control Working Group, Lieutenant General Doni Monardo; Cabinet Secretary, Pramono Anung and the Governor of West Java, Ridwan Kamil.
Erick Thohir visited the PT. Bio Farma pharmaceutical factory in the Faculty of Medicine of UNPAD on August 4 and said that the government needs a lot of money for procurement and vaccination project. According to his estimation, it will cost about US$ 4.5 billion or about 65.9 trillion Rupiah to buy the vaccines, produce and inject them into the 160 million to 190 million Indonesians.
“If the price of each vaccine is $15, how much will it cost in total ? Assuming that we have 300 million vaccines multiplied by US$15 means that it’s worth around US$ 4.5 billion,” Erick said in a video conference interview. (Harian Bisnis Indonesia V)